摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N,2-dicyclohexyl-2-(2-(pyridin-4-yl)-1H-benzo[d]imidazol-1-yl)acetamide | 1266357-66-7

中文名称
——
中文别名
——
英文名称
N,2-dicyclohexyl-2-(2-(pyridin-4-yl)-1H-benzo[d]imidazol-1-yl)acetamide
英文别名
N,2-dicyclohexyl-2-(2-pyridin-4-ylbenzimidazol-1-yl)acetamide
N,2-dicyclohexyl-2-(2-(pyridin-4-yl)-1H-benzo[d]imidazol-1-yl)acetamide化学式
CAS
1266357-66-7
化学式
C26H32N4O
mdl
——
分子量
416.566
InChiKey
JWYJJTYZBIQOGC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.7
  • 重原子数:
    31
  • 可旋转键数:
    5
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    59.8
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

  • 作为产物:
    描述:
    tert-butyl (2-(N-(1-cyclohexyl-2-(cyclohexylamino)-2-oxoethyl)isonicotinamido)phenyl)carbamate 在 三氟乙酸 作用下, 生成 N,2-dicyclohexyl-2-(2-(pyridin-4-yl)-1H-benzo[d]imidazol-1-yl)acetamide
    参考文献:
    名称:
    Discovery of novel and orally active FXR agonists for the potential treatment of dyslipidemia & diabetes
    摘要:
    Herein we describe the synthesis and structure activity relationship of a new class of FXR agonists identified from a high-throughput screening campaign. Further optimization of the original hits led to molecules that were highly active in an LDL-receptor KO model for dyslipidemia. The most promising candidate is discussed in more detail. (C) 2010 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2010.11.039
点击查看最新优质反应信息

文献信息

  • Discovery of novel and orally active FXR agonists for the potential treatment of dyslipidemia & diabetes
    作者:Hans G.F. Richter、Gregory M. Benson、Denise Blum、Evelyne Chaput、Song Feng、Christophe Gardes、Uwe Grether、Peter Hartman、Bernd Kuhn、Rainer E. Martin、Jean-Marc Plancher、Markus G. Rudolph、Franz Schuler、Sven Taylor、Konrad H. Bleicher
    DOI:10.1016/j.bmcl.2010.11.039
    日期:2011.1
    Herein we describe the synthesis and structure activity relationship of a new class of FXR agonists identified from a high-throughput screening campaign. Further optimization of the original hits led to molecules that were highly active in an LDL-receptor KO model for dyslipidemia. The most promising candidate is discussed in more detail. (C) 2010 Elsevier Ltd. All rights reserved.
查看更多